Equities research analysts predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will announce sales of $29.80 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings. The highest sales estimate is $37.09 million and the lowest is $21.66 million. Lexicon Pharmaceuticals reported sales of $23.04 million in the same quarter last year, which indicates a positive year-over-year growth rate of 29.3%. The business is scheduled to issue its next quarterly earnings report on Friday, March 2nd.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year sales of $29.80 million for the current financial year, with estimates ranging from $78.94 million to $94.37 million. For the next fiscal year, analysts anticipate that the company will post sales of $122.05 million per share, with estimates ranging from $110.64 million to $129.40 million. Zacks’ sales averages are an average based on a survey of analysts that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The firm had revenue of $26.94 million for the quarter, compared to the consensus estimate of $27.97 million. During the same period in the prior year, the business posted ($0.35) earnings per share. The firm’s revenue for the quarter was down 2.8% compared to the same quarter last year.
Several equities analysts recently weighed in on LXRX shares. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Wedbush reiterated an “outperform” rating and set a $38.00 target price on shares of Lexicon Pharmaceuticals in a research report on Thursday, November 30th. Needham & Company LLC reiterated a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. Finally, ValuEngine downgraded Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $28.50.
Lexicon Pharmaceuticals (NASDAQ LXRX) traded down $0.09 during midday trading on Wednesday, reaching $9.80. The company had a trading volume of 531,400 shares, compared to its average volume of 591,800. Lexicon Pharmaceuticals has a 1 year low of $8.07 and a 1 year high of $18.00. The stock has a market capitalization of $1,030.00, a P/E ratio of -7.72 and a beta of 0.10. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65.
In other news, Director Public Equities L.P. Invus acquired 145,680 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were bought at an average cost of $9.74 per share, for a total transaction of $1,418,923.20. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Lonnel Coats acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was purchased at an average price of $9.91 per share, for a total transaction of $99,100.00. Following the completion of the acquisition, the chief executive officer now owns 42,985 shares in the company, valued at $425,981.35. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 914,353 shares of company stock worth $8,916,253. Company insiders own 5.77% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $182,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $149,000. C WorldWide Group Holding A S raised its holdings in shares of Lexicon Pharmaceuticals by 49.6% during the 3rd quarter. C WorldWide Group Holding A S now owns 16,146 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 5,353 shares during the period. Legal & General Group Plc raised its holdings in shares of Lexicon Pharmaceuticals by 2.6% during the 2nd quarter. Legal & General Group Plc now owns 18,570 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 465 shares during the period. Finally, 361 Capital LLC raised its holdings in shares of Lexicon Pharmaceuticals by 91.8% during the 2nd quarter. 361 Capital LLC now owns 24,874 shares of the biopharmaceutical company’s stock valued at $409,000 after buying an additional 11,904 shares during the period.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/10/zacks-analysts-expect-lexicon-pharmaceuticals-inc-lxrx-will-announce-quarterly-sales-of-29-80-million.html.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.